Exact Mass: 393.1477194
Exact Mass Matches: 393.1477194
Found 75 metabolites which its exact mass value is equals to given mass value 393.1477194,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
gamma-Glutamylfelinylglycine
1-[5-(2-Cyclopropyl-5,7-dimethylimidazo[4,5-b]pyridin-3-ylmethyl)thiophen-2-yl]cyclopent-3-ene carboxylic acid
4-(2-Aminoethylamino)-3-[bis(carboxymethyl)amino]-3-(carboxymethyl)hexanedioic acid
6-(1-hydroxyethyl)-5,6-dihydrochelerythrine
C23H23NO5 (393.15761480000003)
6-(1-Hydroxyethyl)-5,6-dihydrochelerythrine
C23H23NO5 (393.15761480000003)
AMG-073 HCl (Cinacalcet hydrochloride)
C22H23ClF3N (393.14710240000005)
Asn Ser Ser Ser
Ser Asn Ser Ser
Ser Ser Asn Ser
Ser Ser Ser Asn
Pentetic acid
D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents D020011 - Protective Agents > D000931 - Antidotes
7-FLUORO-3,4-DIHYDRO-4-[(5-ISOQUINOLINYLOXY)ACETYL]-1,3,3-TRIMETHYL-2(1H)-QUINOXALINONE
C22H20FN3O3 (393.14886220000005)
2,6-BIS((3AS,8AR)-8,8A-DIHYDRO-3AH-INDENO[1,2-D]OXAZOL-2-YL)PYRIDINE
Cinacalcet hydrochloride
C22H23ClF3N (393.14710240000005)
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D057966 - Calcimimetic Agents C78275 - Agent Affecting Blood or Body Fluid > C2136 - Malignancy-Associated Hypercalcemia Inhibitor D000077264 - Calcium-Regulating Hormones and Agents
5-(6-(BENZYLOXY)NAPHTHALEN-2-YL)-2,2-DIMETHYL-5-NITRO-1,3-DIOXANE
C23H23NO5 (393.15761480000003)
4-Cyanophenyl 4-(6-acryloyloxyhexyloxy)benzoate
C23H23NO5 (393.15761480000003)
methyl 2-[(3-cyanobenzoyl)amino]-3-(3-methoxypropyl)imidazo[4,5-b]pyridine-6-carboxylate
C20H19N5O4 (393.14369740000006)
BOC-THIONOLEU-1-(6-NITRO)BENZOTRIAZOLIDE
C17H23N5O4S (393.14706780000006)
7-[2-[[(1S,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]ethyl]-1,3-dimethylpurine-2,6-dione,hydrochloride
C18H24ClN5O3 (393.15675840000006)
2,6-BIS((3AR,8AS)-8,8A-DIHYDRO-3AH-INDENO[1,2-D]OXAZOL-2-YL)PYRIDINE
4-(3-(4-(1-methyl-1H-pyrazol-5-yl)phenylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide
PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) (IC50=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective in inflammation and pain[1].
2-fluoro-N-[4-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]phenyl]benzamide
C22H20FN3O3 (393.14886220000005)
1-(3,4-dihydro-2H-quinolin-1-yl)-2-[[1-(4-ethoxyphenyl)-2-imidazolyl]thio]ethanone
3-[(2E,4E,6E)-6,8-dimethyldeca-2,4,6-trienoyl]-1-hydroxy-5-(4-oxidophenyl)-2-oxopyridin-4-olate
C23H23NO5-2 (393.15761480000003)
1-[4-(4-Phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide
N-(3-imidazol-1-ylpropyl)-2-[(4-nitrobenzoyl)amino]benzamide
C20H19N5O4 (393.14369740000006)
N-{(E)-[2,4,6-trioxo-1-(2,4,6-trimethylphenyl)tetrahydropyrimidin-5(2H)-ylidene]methyl}pyridine-4-carbohydrazide
C20H19N5O4 (393.14369740000006)
2,5-Dimethyl-3-furancarboxylic acid [2-(2-ethoxyanilino)-2-oxo-1-phenylethyl] ester
C23H23NO5 (393.15761480000003)
[(1S,2aR,8bR)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-fluorophenyl)methanone
C22H20FN3O3 (393.14886220000005)
[(1R,2aS,8bS)-1-(hydroxymethyl)-2-(4-oxazolylmethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-fluorophenyl)methanone
C22H20FN3O3 (393.14886220000005)
Cyclohexyl 2-methyl-4-thiophen-2-yl-3,4-dihydropyrimido[1,2-a]benzimidazole-3-carboxylate
(2,5-Dioxopyrrolidin-1-yl) 4-(3,6-diaminoacridin-10-ium-10-yl)butanoate
Agomelatine (L(+)-Tartaric acid)
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
CJ-13,610
CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM[1]. PMNL: polymorphonuclear leukocytes; AA: arachidonic acid
1-[(6s)-2,3-dihydroxy-7,8-dimethoxy-5-methyl-6h-benzo[c]phenanthridin-6-yl]propan-2-one
C23H23NO5 (393.15761480000003)
20-ethoxy-17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14(19),15,17-octaene
C23H23NO5 (393.15761480000003)
(1s)-1-[(20s)-17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-yl]ethanol
C23H23NO5 (393.15761480000003)
(1s,12s,13r)-12-hydroxy-5-methoxy-12-(2-methoxyphenyl)-6-methyl-16-oxa-7-azatetracyclo[11.2.1.0²,¹¹.0³,⁸]hexadeca-2,5,8,10-tetraen-4-one
C23H23NO5 (393.15761480000003)
(1r,12s,13s)-12-hydroxy-5-methoxy-12-(2-methoxyphenyl)-6-methyl-16-oxa-7-azatetracyclo[11.2.1.0²,¹¹.0³,⁸]hexadeca-2,5,8,10-tetraen-4-one
C23H23NO5 (393.15761480000003)
(1s,12r,13r)-12-hydroxy-5-methoxy-12-(2-methoxyphenyl)-6-methyl-16-oxa-7-azatetracyclo[11.2.1.0²,¹¹.0³,⁸]hexadeca-2,5,8,10-tetraen-4-one
C23H23NO5 (393.15761480000003)
2-[(1r,3s,4ar,10ar)-4a,9,10a-trihydroxy-7-methoxy-5,10-dioxo-1-propyl-1h,3h,4h-naphtho[2,3-c]pyran-3-yl]ethanimidic acid
(21r)-5,10,11-trimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11,19-octaene-6,21-diol
C23H23NO5 (393.15761480000003)
n-{2-[12-methoxy-11-(methylsulfanyl)-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,9,11,13,15-octaen-10-yl]ethyl}propanimidic acid
1-{17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-yl}ethanol
C23H23NO5 (393.15761480000003)
5,10,11-trimethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11,19-octaene-6,21-diol
C23H23NO5 (393.15761480000003)